共 158 条
[1]
Cohen JA(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med. 362 402-15
[2]
Barkhof F(2020)Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients Ann Neurol. 87 688-99
[3]
Comi G(2017)Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort Brain Behav. 7 23106-27
[4]
Hartung HP(2016)The emerging role of FTY720 (Fingolimod) in cancer treatment Oncotarget. 7 329-36
[5]
Khatri BO(2007)Sphingosine-1-Phosphate Signaling and the Skin Am J Clin Dermatol 8 563-8
[6]
Montalban X(2021)Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients Cancer Immunology, Immunotherapy. 70 1389-401
[7]
Alping P(2020)Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study</p> Clinical Epidemiology. 12 372-6
[8]
Askling J(2020)Skin cancer screening in organ transplant centres in the United Kingdom: a national survey Eur J Dermatol 30 17-24
[9]
Burman J(2006)FTY720 (fingolimod) in renal transplantation Clin Transplant. 20 970-2
[10]
Fink K(2017)Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS Neurology. 89 427-8